Compare Amphastar Pharmaceuticals Inc (AMPH) vs Fox Corp Class B (FOX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

FOX stock trades at $48.75, up 0.64% today, amid a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.41. The company's 2025 revenue surged to $16.3B, driving net income to $2.26B, while cash flow turned positive at $1.03B. Key developments include the $22B Roku acquisition, highlighting strategic moves in streaming, though leverage concerns have pressured the stock, which is down 25% over four weeks as of June 26, 2026 (Zacks Investment Research).

The outlook balances robust fundamentals against near-term headwinds. Valuation appears attractive with a P/E of 12.83 and EV/EBITDA of 8.19, but integration risks from the Roku deal and bearish technical trends pose challenges. Analyst consensus is mixed (42.86% Buy, 47.62% Hold), suggesting cautious optimism for long-term growth driven by streaming expansion and advertising recovery, though volatility may persist.